Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Second Primary 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1Asymptomatic Brain Metastases 1

Interventions

Paclitaxel 71Bevacizumab 64Carboplatin 56pembrolizumab 46olaparib 32Gemcitabine 29Specimen Handling 27Cyclophosphamide 26liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 21Taxes 19Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 13Disulfides 13Fulvestrant 12Blood Specimen Collection 11durvalumab 10Oxaliplatin 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Tyrosine Kinase Inhibitors × 1 year × Clear all
NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡